Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach. | Clin Transl Oncol | 2026 | 41533296 | PubTator, text mining | PubMed |
| TROP2 Promotes Tumor Cell Migration through Downregulation of DSG2 Revealed by Super-Resolution Fluorescence Imaging. | Anal Chem | 2026 | 41531208 | PubTator, text mining | PubMed |
| Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients. | BMC Med | 2026 | 41530754 | PubTator, text mining | PubMed |
| Advances on drug therapy for KRASG12C-mutant non-small-cell lung cancer. | Transl Oncol | 2026 | 41529383 | PubTator, text mining | PubMed |
| Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer. | Cancer Treat Rev | 2026 | 41512604 | PubTator, text mining | PubMed |
| CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer. | Cell Mol Life Sci | 2026 | 41511527 | PubTator, text mining | PubMed |
| Sarcomatoid urothelial carcinoma: advances and challenges. | Curr Opin Urol | 2026 | 41505638 | PubTator, text mining | PubMed |
| A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. | Biomol Biomed | 2026 | 41499692 | PubTator, text mining | PubMed |
| MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. | Future Oncol | 2026 | 41495607 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms. | Gastric Cancer | 2026 | 41484653 | PubTator, text mining | PubMed |
| Feedback regulation between histone H3 lysine 18 lactylation and TROP2-mediated glycolysis drives metastatic progression of colorectal cancer. | Clin Transl Med | 2026 | 41482854 | PubTator, text mining | PubMed |
| A multifunctional nanozyme integrating panoptosis induction and T-cell metabolic reprogramming to augment the efficacy of PD-1 inhibitors. | Colloids Surf B Biointerfaces | 2026 | 41481959 | PubTator, text mining | PubMed |
| Disulfide-Directed Multicyclic Peptides for Chimeric Antigen Receptors Targeting Solid Tumors. | J Am Chem Soc | 2026 | 41480930 | PubTator, text mining | PubMed |
| Nonglycosylated, Legumain-Cleavable ISACs Drive Potent Antitumor Immunotherapy via a Bystander Effect. | Mol Cancer Ther | 2026 | 41472556 | PubTator, text mining | PubMed |
| Molecular alteration profiles characterize intraductal carcinoma of the prostate. | Cancer | 2026 | 41457395 | PubTator, text mining | PubMed |
| Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential. | Target Oncol | 2026 | 41456235 | PubTator, text mining | PubMed |
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. | Ann Oncol | 2026 | 41448362 | PubTator, text mining | PubMed |
| Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer. | Prostate Cancer Prostatic Dis | 2026 | 41444470 | PubTator, text mining | PubMed |
| TROP-2-directed antibody-drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes. | Crit Rev Oncol Hematol | 2026 | 41443486 | PubTator, text mining | PubMed |
| Expression of Transmembrane Glycoprotein TROP2 in Triple-Negative Breast Cancer and It's Potential as a Molecular Classifier for Targeted Therapy. | Cancer Invest | 2026 | 41403267 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=18